Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study

BMC Nephrology

Amit X Garg¹  Matthew A Weir⁵  Davy Tawadrous⁴  Salimah Z Shariff⁶  Arsh K Jain⁵  Ziv Harel²  Tara Gomes⁷  Sonja Gandhi⁵  Jamie L Fleet⁴  Stephanie N Dixon⁶  Varun Dev³ 

[1] London Kidney Clinical Research Unit, Room ELL-101, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada;Division of Nephrology, University of Toronto, Toronto, Ontario, Canada;Schulich School of Medicine, Western University, London, Canada;Division of Nephrology, Western University, London, Ontario, Canada;Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada;Institute for Clinical Evaluative Sciences, Ontario, Canada;Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada

关键词: Risk;    Cohort studies;    Chronic renal insufficiency;    Aged;    Delirium;    Anti-depressant;   

Others  :  1082683
DOI  :  10.1186/1471-2369-15-79

 received in 2014-01-06, accepted in 2014-05-01,  发布年份 2014

【 摘 要 】

Background

Many older patients have chronic kidney disease (CKD), and a lower dose of anti-depressants paroxetine, mirtazapine and venlafaxine is recommended in patients with CKD to prevent drug accumulation from reduced elimination. Using information available in large population-based healthcare administrative databases, we conducted this study to determine if ignoring the recommendation and prescribing a higher versus lower dose of anti-depressants associates with a higher risk of adverse events.

Methods

We conducted a population-based cohort study to describe the 30-day risk of delirium in older adults who initiated a higher vs. lower dose of these three anti-depressants in routine care. We defined delirium using the best proxy available in our data sources - hospitalization with an urgent head computed tomography (CT) scan. We determined if CKD status modified the association between anti-depressant dose and outcome, and examined the secondary outcome of 30 day all-cause mortality. We used multivariable logistic regression analyses to estimate adjusted odds ratios (relative risk (RR)) and 95% confidence intervals.

Results

We identified adults (mean age 75) in Ontario who started a new study anti-depressant at a higher dose (n = 36,651; 31%) or lower dose (n = 81,160; 69%). Initiating a higher vs. lower dose was not associated with an increased risk of hospitalization with head CT (1.09% vs. 1.27% (adjusted RR 0.90; 95% CI, 0.80 to 1.02), but was associated with a lower risk of all-cause mortality (0.76% vs. 0.97% RR 0.82; 95% CI, 0.71 to 0.95). Neither of these relative risks were modified by the presence of CKD (p = 0.16, 0.68, respectively).

Conclusions

We did not observe an increase in two adverse outcomes when study anti-depressants were initiated at a higher dose in elderly patients with moderate CKD. Contrary to our hypothesis, the 30-day risk of mortality was lower when a higher versus lower dose of anti-depressant was initiated in these patients, a finding which requires corroboration and further study.

【 授权许可】

   
2014 Dev et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Wiese BS: Geriatric depression: The use of antidepressants in the ederly. BC Med J 2011, 53(7):341-347.
• [2]Gunnell D, Ashby D: Antidepressants and suicide: what is the balance of benefit and harm. BMJ (Clinical research ed) 2004, 329(7456):34-38. doi:10.1136/bmj.329.7456.34
• [3]Exeter D, Robinson E, Wheeler A: Antidepressant dispensing trends in New Zealand between 2004 and 2007. Aust N Z J Psychiatry 2009, 43(12):1131-1140. doi:10.3109/00048670903279879
• [4]Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T: Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009., 339(b39999) doi:10.1136/bmj.b3999
• [5]Austin PC, Ph D, Upshur REG, Sc M: Use of Antidepressants Among Elderly Subjects: Trends and Contributing Factors. Am J Psychiatry 2000, 157:360-367.
• [6]Nagler EV, Webster AC, Vanholder R, Zoccali C: Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012, 27(10):3736-3745. doi:10.1093/ndt/gfs295
• [7]Smith GC, Clarke DM, Handrinos D, Trauer T: Adverse reactions to antidepressants in consultation-liaison psychiatry inpatients. Psychosomatics 2002, 43(3):228-33. doi:10.1176/appi.psy.43.3.228
• [8]Dormann H, Sonst A, Müller F, Vogler R, Patapovas A, Pfistermeister B, Plank-Kiegele B, Kirchner M, Hartmann N, Bürkle T, Maas R: Adverse drug events in older patients admitted as an emergency: the role of potentially inappropriate medication in elderly people (PRISCUS). Dtsch Arztebl Int 2013, 110(13):213-9. doi:10.3238/arztebl.2013.0213
• [9]Routledge PA, O’Mahony MS, Woodhouse KW: Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2003, 57(2):121-126. doi:10.1046/j.1365-2125.2003.01875.x
• [10]Group, KDIGO (KDIGO) CW: KDIGO: Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2012, 2013(3):1-150.
• [11]Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, Kuhlmann MK, Schuchardt M, Tolle M, Ziebig R, van der Giet M, Martus P: Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2013, 157(7):471-481.
• [12]Cohen LM, Tessier EG, Germain MJ, Levy NB: Update on psychotropic medication use in renal disease. Psychosomatics 2004, 45(1):34-48. doi:10.1176/appi.psy.45.1.34
• [13]Crone CC, Gabriel GM: Treatment of anxiety and depression pharmacokinetic considerations. Clin Pharmacokinet 2004, 43(6):361-394.
• [14]Baghdady NT, Banik S, Swartz SA, McIntyre RS: Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 2009, 26(4):404-424. doi:10.1007/s12325-009-0021-x
• [15]Bailer U, Fischer P, Küfferle B, Stastny J, Kasper S: Occurrence of mirtazapine-induced delirium in organic brain disorder. Int Clin Psychopharmacol 2000, 15(4):239-243. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10954066 webcite
• [16]Alexander J, Nillsen A: Venlafaxine-induced delirium. Aust N Z J Psychiatry 2011, 45(7):606. doi:10.3109/00048674.2011.567968
• [17]Chuang Y-F, Chiu Y-L, Hwang T-J, Chu T-S: Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure. Psychiatry Clin Neurosci 2006, 60(5):642-643. doi:10.1111/j.1440-1819.2006.01574.x
• [18]Wakeno M, Okugawa G, Takekita Y, Kato M, Fukuda T, Yamashita M, Hosoi Y, Azuma J: Delirium associated with paroxetine in an elderly depressive patient: a case report. Pharmacopsychiatry 2007, 40(5):199-200. doi:10.1055/s-2007-985882
• [19]UpToDate V21.1. Mirtazapine: Drug Information. http://www-uptodate- com.proxy2.lib.uwo.ca/contents/mirtazapine-drug- information?source=search_result&search=mirtazapine&selectedTitle=1~49 webcite. Accessed on: 5-11-2013
• [20]UpToDate V21.1. Venlafaxine: Drug Information. http://www-uptodate- com.proxy2.lib.uwo.ca/contents/venlafaxine-drug- information?source=search_result&search=venlafaxine&selectedTitle=1~96 webcite. Accessed on: 5-11-2013
• [21]UpToDate V21.1. Paroxetine: Drug Information. http://www-uptodate- com.proxy2.lib.uwo.ca/contents/paroxetine-drug- information?source=search_result&search=paroxetine&selectedTitle=1~127 webcite. Accessed on 5-11-13
• [22]Paxil [product monograph]: Compendium of Pharmaceuticals and Specialties. Ottawa, Canada: Canadian Pharmacists Association; 2008:1645-1655.
• [23]Effexor [product monograph]: Compendium of Pharmaceuticals and Specialties. Ottawa, Canada: Canadian Pharmacists Association; 2008:766-776.
• [24]Remeron [product monograph]: Compendium of Pharmaceuticals and Specialties. Ottawa, Canada: Canadian Pharmacists Association; 2008:1908-1911.
• [25]Canada S: Population by sex and age group, by province and territory. Ottawa: Statistics Canada; 2012. Available at: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo31a-eng.htm webcite
• [26]Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008, 61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
• [27]Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D: Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003, 10(2):67-71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12879144 webcite
• [28]Gandhi S, Shariff SZ, Beyea MM, Weir MA, Hands T, Kearns G, Garg AX: Identifying geographical regions serviced by hospitals to assess laboratory-based outcomes. BMJ open 2013, 3(1):1-6. doi:10.1136/bmjopen-2012-001921
• [29]Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Moist L, Parikh CR, Paterson JM, Wald R, Yao Z, Garg AX: New fibrate use and acute renal outcomes in elderly adults: a population- based study. Ann Intern Med 2012, 156(8):560-569.
• [30]Shih AW, Weir MA, Clemens KK, Yao Z, Gomes T, Mamdani MM, Juurlink DN, Hird A, Hodsman A, Parikh CR, Wald R, Cadarette SM, Garg AX: Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int 2012, 82(8):903-908.
• [31]Lam NN, Weir MA, Yao Z, Blake PG, Beyea MM, Gomes T, Gandhi S, Mamdani M, Wald R, Parikh CR, Hackam DG, Garg AX: Risk of acute kidney injury from oral acyclovir: A population-based study. Am J Kidney Dis 2013, 61(5):723-729.
• [32]Fleet JL, Dixon SN, Shariff SZ, Quinn RR, Nash DM, Harel Z, Garg AX: Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol 2013, 14:81. BioMed Central Full Text
• [33]Mitsch AL: Antidepressant adverse drug reactions in older adults: Implications for RNs and APNs. Geriatric nursing (New York, NY) 2012, 34(1):53-61.
• [34]Williams J, Young W: A summary of studies on the quality of health care administrative databases in Canada. Ottawa: Canadian Medical Association; 1996:339-45.
• [35]Jha P, Deboer D, Sykora K, Naylor C: Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol 1996, 27:1335-1342.
• [36]Austin P: Using the standardized difference to compare the prevalence of a binary variable between Two groups in observational research. Communication in Statistics - Simulation and Computation 2009, 38:1228-1234.
• [37]Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiller D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Jouven X, Ducimetiere P, PRIME Study Group: Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005, 111(18):2299-2305. doi:10.1161/01.CIR.0000164203.54111.AE
• [38]Barefoot JC, Burg MM, Carney RM, Cornell CE, Czajkowski SM, Freedland KE, Hosking JD, Khatri P, Pitula CR, Sheps D: Aspects of social support associated with depression at hospitalization and follow-up assessment among cardiac patients. J Cardpulm Rehabil 2003, 23(6):404-412. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14646786 webcite
• [39]Bonnet F, Irving K, Terra J-L, Nony P, Berthezène F, Moulin P: Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis 2005, 178(2):339-344. doi:10.1016/j.atherosclerosis.2004.08.035
• [40]Koo JR, Yoon JW, Kim SG, Lee YK, Oh KH, Kim GH, Kim HJ, Chae DW, Noh JW, Lee SK, Son BK: Association of depression with malnutrition in chronic hemodialysis patients. Am J Kidney Dis 2003, 41(5):1037-1042. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12722038 webcite
• [41]Ontario Ministry of Finance: Ontario Population Projections 2011–2036: Ontario and Its 49 Census Divisions. Toronto: Queen’s Printer for Ontario; 2012. Ref Type: Report